Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: Nationwide cohort study

BMJ (Online)

Volumn 344, Issue 7851, 2012, Pages

  Bretler, Ditte Marie ^a   Hansen, Peter Riis ^a   Sørensen, Rikke ^b   Lindhardsen, Jesper ^a   Ahlehoff, Ole ^a   Andersson, Charlotte ^a   Abildstrøm, Steen Zabell ^b   Torp Pedersen, Christian ^a,c   Gislason, Gunnar Hilmar ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DENMARK; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART INFARCTION; HEART PROTECTION; HEART REINFARCTION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MORTALITY; PREDICTIVE VALUE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; AGED; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; POSTMENOPAUSE; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TREATMENT WITHDRAWAL;

ADULT; AGED; CAUSE OF DEATH; DENMARK; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTMENOPAUSE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 84859548616     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e1802     Document Type: Article

References (45)

1. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992;117:1038-41.
2. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72. (Pubitemid 28279924)
3. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
6. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:1481-501. (Pubitemid 46648385)
7. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-93. (Pubitemid 38198877)
8. Naftolin F, Schneider HP, Sturdee DW, Birkhauser M, Brincat MP, Gambacciani M, et al. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004;7:333-7. (Pubitemid 40018326)
9. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11. (Pubitemid 29266405)
10. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, Bergholm R, Ehnholm C, Hovatta O, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 2000;102:2687-93.
11. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003;41:1358-63. (Pubitemid 36438997)
12. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-25. (Pubitemid 32293696)
13. Vrablik M, Fait T, Kovar J, Poledne R, Ceska R. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism 2008;57:1088-92. (Pubitemid 351978068)
14. Labrie F, Cusan L, Gomez JL, Cote I, Berube R, Belanger P, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30-6.
15. Greiner DZ, Personius BE, Andrews TC. Effects of withdrawal of chronic estrogen therapy on brachial artery vasoreactivity in women with coronary artery disease. Am J Cardiol 1999;83:247-9, A5.
16. Kalela A, Jokela H, Lehtimaki T, Uppa H, Kunnas T, Teisala K, et al. Effect of the cessation of long-term hormone replacement therapy on plasma plasminogen activator inhibitor-1 and fibrinogen. Eur J Obstet Gynecol Reprod Biol 2006;125:217-20.
17. Pettee KK, Kriska AM, Conroy MB, Johnson BD, Orchard TJ, Goodpaster BH, et al. Discontinuing hormone replacement therapy: attenuating the effect on CVD risk with lifestyle changes. Am J Prev Med 2007;32:483-9. (Pubitemid 46803172)
18. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med 2005;118(suppl 12B):163-5.
19. Haimov-Kochman R, Barak-Glantz E, Ein-Mor E, Arbel R, Brzezinski A, Milwidsky A, et al. Duration not severity of the climacteric syndrome predicts resumption of hormone therapy after discontinuation: a prospective cohort study. Hum Reprod 2006;21:2450-4. (Pubitemid 44530627)
20. Horner E, Fleming J, Studd J. A study of women on long-term hormone replacement therapy and their attitude to suggested cessation. Climacteric 2006;9:459-63. (Pubitemid 44691461)
21. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
22. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient. Circulation 2004;110:1926-32. (Pubitemid 39331903)
23. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12. (Pubitemid 34728951)
24. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60. (Pubitemid 29094296)
25. Bretler DM, Hansen PR, Abildstrom SZ, Jorgensen CH, Sorensen R, Hansen ML, et al. Use and discontinuation of hormone replacement therapy in women with myocardial infarction: a nationwide study. Br J Clin Pharmacol 2011;71:105-15.
26. Nordic Medico-Statistical Committee (NOMESCO). NOMESCO Classification of Surgical Procedures (NCSP), version 1.15. NOMESCO, 2010 (available at http://nomesco-da.nomnos.dk/filer/publikationer/NCSP%201-15.pdf).
27. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-8. (Pubitemid 27382061)
28. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56:124-30. (Pubitemid 36315938)
29. Olesen JB, Hansen PR, Abildstrom SZ, Andersson C, Weeke P, Schmiegelow M, et al. Valproate attenuates the risk of myocardial infarction in patients with epilepsy: a nationwide cohort study. Pharmacoepidemiol Drug Saf 2011;20:146-53.
30. Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol 2001;37:992-7. (Pubitemid 32217595)
31. Vermeulen MJ, Tu JV, Schull MJ. ICD-10 adaptations of the Ontario acute myocardial infarction mortality prediction rules performed as well as the original versions. J Clin Epidemiol 2007;60:971-4. (Pubitemid 47198452)
32. Kumler T, Gislason GH, Kirk V, Bay M, Nielsen OW, Kober L, et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 2008;10:658-60.
33. Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153-8.
34. Buch P, Rasmussen S, Gislason GH, Rasmussen JN, Kober L, Gadsboll N, et al. Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002. Heart 2007;93:210-5. (Pubitemid 46180297)
35. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
36. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303. (Pubitemid 43797117)
37. Yeboah J, Klein K, Brosnihan B, Reboussin D, Herrington DM. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. Menopause 2008;15:1060-4.
38. Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2660-8.
39. Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA, MacLennan AH, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:a1190.
40. Shlipak MG, Angeja BG, Go AS, Frederick PD, Canto JG, Grady D. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001;104:2300-4. (Pubitemid 33049512)
41. Khan MA, Liu MW, Singh D, Pal A, Chio FL, Lawson D, et al. Long-term (three years) effect of estrogen replacement therapy on major adverse cardiac events in postmenopausal women after intracoronary stenting. Am J Cardiol 2000;86:330-3. (Pubitemid 30462233)
42. Raunso J, Selmer C, Olesen JB, Charlot MG, Olsen AM, Bretler DM, et al. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J 2011; published online 23 December.
43. Gorodeski EZ. Are hot flashes linked to cardiovascular risk? It is too early to tell. Menopause 2010;17:443-4.
44. Collet JP, Montalescot G, Steg PG, Steinhubl SR, Fox KA, Hu TF, et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis 2009;102:485-96.
45. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15.